MedWatch

US institution changes share price target for three big Danish drugmakers

Three of Denmark’s biggest life science firms, Novo Nordisk, Lundbeck and Genmab, have had their share price target adjusted by a private wealth manager in the US.

Photo: Jens Dresling

US-based private wealth manager Bernstein has taken stock of three large Danish drugmakers – Novo Nordisk, Lundbeck and Genmab – resulting in share price target changes for all three, Bloomberg News reports.

Bernstein has increased Novo Nordisk’s target to DKK 800 from DKK 750 (USD 117 from 109), labeling the stock ”outperform.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs